Ongentys
Chemical Name | opicapone |
Dosage Form | Capsules (oral; 25 mg, 50 mg) |
Drug Class | Inhibitors |
System | Nervous |
Company | Neurocrine Biosciences, Inc. |
Approval Year | 2020 |
Indication
- Indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.